You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
    • Ahead of the Curve
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • RSS
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >The Healthcare sector...
Story Stocks® Archive
Last Update: 19-Dec-12 10:42 ET
The Healthcare sector (-0.35%) is trading lower today, underperforming the S&P 500 (-0.15%)

General Commentary: This morning's biggest mover is Oncothyreon (ONTY) which is down over 50%. The company announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer (NSCLC). Oncothyreon is not completely giving up on the drug, stating, "Despite not meeting the primary endpoint, notable treatment effects were seen for L-BLP25 in certain subgroups. Further analyses are planned in the coming weeks to explore the potential benefit-risk profile of L-BLP25 in certain populations."

Gainers on news:

  • Ideara Pharmaceuticals (IDRA +25.97%) Reported positive top-line results from Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis
  • Sequenom (SQNM +8.41%) Strength being attributed to news that Wellpoint (WLP) said the co's MaterniT21 Test was medically necessary
Decliners on news:
  • Oncothyreon (ONTY -58.33%) Announced that L-BLP25 (Stimuvax) did not meet primary endpoint of improvement in overall survival in pivotal Phase 3 trial in patients with non-small cell lung cancer
  • Hemispherx Biopharma (HEB -2.99%) Continued weakness following critical brieifing documents ahead of FDA panel to review Ampligen for the treatment of Chronic Fatigue Syndrome
Gainers on earnings: No notable gainers on earnings

Decliners on earnings:

  • Health Net (HNT -1.91%) Sees 2013 GAAP EPS of $2.00-2.10 vs $2.15 estimate; projects total health plan memebership will decline by 1-2%

Upgrades/Downgrades:

  • Antares Pharmaceuticals (ATRS +1.05%) Initiated with a Buy at Jefferies
  • Omnicell (OMCL +0.57%) Initiated with a Market Perform at Wells Fargo
  • C.R. Bard (BCR +0.33%) Initiated with a Market Outperform at JMP Securities
  • Greenway Medical (GWAY 0.00%) Initiated with a Market Perform at Wells Fargo
  • Onyx Pharmaceuticals (ONXX -1.14%) Initiated with a Buy at UBS
General Commentary: This morning's biggest mover is Oncothyreon (ONTY) which is down over 50%. The company announced that the pivotal Phase 3
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Custom Tickers
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup